Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money
In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List
Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now
Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels
Workshop Calls For Improved Surgical Oncology Training Programs
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - Insights from ASCO 2025: Real-world evidence drives clinical decision-making
- In the Headlines: Missing record of NCAB meetings restored to NIH website
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”
